Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bioteque Corporation (4107.TWO)
Taipei, TW
Established in Taipei, Taiwan, in 1991, Bioteque Corporation operates as a global manufacturer and supplier of medical devices, serving markets across Asia, South America, North America, and other international regions. The company specializes in a diverse range of medical disposables, critical for applications such as hemodialysis access and endovascular treatments. Its comprehensive product line features dialysis equipment, including bloodlines, A.V.F. needles, and hemodialysis catheters; interventional radiology solutions like pigtail drainage catheter sets and introducer sets; and urology essentials such as ureteral stent sets and urine collection bags. Furthermore, Bioteque offers IV administration products, including PVC infusion bags and twist-off ports; respiratory care items like closed suction catheters and endotracheal tubes; and a suite of vascular access products, including angiographic catheters, PTA balloon dilatation catheters, and guidewires. The company also manufactures a wide array of specialized medical components, such as dialyzer connectors, various luer lock connectors, filters, clamps, and transducer protectors, alongside medical masks.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.41% | +3.88% | -1.63% | +1.69% | -6.23% | +0.00% | -5.86% | +5.70% | +7.11% | -20.20% | +1,038.94% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+3.0% Q1'26: +5.4% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+2.4% Q1'26: +8.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+27.6% Q1'26: +34.9% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+31.4% ★ Q1'26: +32.2% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+21.1% ★ Q1'26: +21.9% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.5% ★ Q1'26: -0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.71× ★ Q1'26: 0.85× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.26B
est: 1.27B (-0.7%)
|
1.41B
est: 1.41B (0.0%)
|
1.42B
est: 1.42B (+0.4%)
|
1.61B
est: 1.63B (-1.0%)
|
1.86B
est: 1.89B (-1.6%)
|
1.95B
est: 1.95B (-0.3%)
|
1.83B
est: 2.04B (-10.6%)
|
2.01B
est: 1.98B (+1.8%)
|
1.94B
est: 2.20B (-11.7%)
|
2.07B
est: 1.98B (+4.7%)
|
2.14B
est: 2.28B (-6.4%)
|
2.15B
2.15B – 2.15B
-5.7% YoY
|
| EBITDA |
441.14M
est: 481.06M (-8.3%)
|
517.43M
est: 533.79M (-3.1%)
|
471.86M
est: 536.92M (-12.1%)
|
604.14M
est: 618.21M (-2.3%)
|
690.64M
est: 717.04M (-3.7%)
|
714.93M
est: 740.94M (-3.5%)
|
662.30M
est: 774.32M (-14.5%)
|
759.13M
est: 749.28M (+1.3%)
|
737.08M
est: 835.40M (-11.8%)
|
850.60M
est: 870.12M (-2.2%)
|
841.83M
est: 1.00B (-16.0%)
|
945.07M
945.07M – 945.07M
-5.7% YoY
|
| EBIT |
404.23M
est: 392.67M (+2.9%)
|
444.08M
est: 435.71M (+1.9%)
|
395.90M
est: 438.27M (-9.7%)
|
489.19M
est: 504.61M (-3.1%)
|
580.49M
est: 585.28M (-0.8%)
|
603.05M
est: 604.79M (-0.3%)
|
547.93M
est: 632.04M (-13.3%)
|
578.38M
est: 611.61M (-5.4%)
|
581.12M
est: 681.90M (-14.8%)
|
687.74M
est: 675.33M (+1.8%)
|
670.28M
est: 778.16M (-13.9%)
|
733.50M
733.50M – 733.50M
-5.7% YoY
|
| Net Income |
315.77M
est: 330.06M (-4.3%)
|
358.23M
est: 362.09M (-1.1%)
|
303.94M
est: 314.16M (-3.3%)
|
405.00M
est: 399.87M (+1.3%)
|
464.17M
est: 478.03M (-2.9%)
|
488.67M
est: 470.02M (+4.0%)
|
431.26M
est: 548.71M (-21.4%)
|
493.54M
est: 487.78M (+1.2%)
|
452.55M
est: 497.18M (-9.0%)
|
528.26M
est: 537.80M (-1.8%)
|
539.19M
est: 562.75M (-4.2%)
|
562.75M
562.75M – 562.75M
+0.0% YoY
|
| SGA |
128.60M
est: 117.80M (+9.2%)
|
131.59M
est: 130.72M (+0.7%)
|
137.73M
est: 131.48M (+4.8%)
|
161.89M
est: 151.39M (+6.9%)
|
184.99M
est: 175.59M (+5.4%)
|
173.05M
est: 181.44M (-4.6%)
|
186.11M
est: 189.62M (-1.8%)
|
196.19M
est: 183.49M (+6.9%)
|
168.32M
est: 204.58M (-17.7%)
|
185.65M
est: 181.58M (+2.2%)
|
176.94M
est: 209.23M (-15.4%)
|
197.22M
197.22M – 197.22M
-5.7% YoY
|
| EPS |
4.07
est: 4.74 (-14.1%)
|
5.17
est: 5.20 (-0.6%)
|
4.39
est: 4.51 (-2.7%)
|
5.84
est: 5.74 (+1.7%)
|
6.70
est: 6.87 (-2.4%)
|
7.05
est: 6.75 (+4.4%)
|
6.22
est: 7.88 (-21.1%)
|
7.12
est: 7.01 (+1.6%)
|
6.53
est: 7.14 (-8.5%)
|
7.64
est: 7.76 (-1.5%)
|
7.78
est: 8.12 (-4.2%)
|
8.12
8.12 – 8.12
+0.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 84.6K | 0.46% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 512.3K | 0.06% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 11.0K | 0.56% |
| 4 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 3.7K | 0.42% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 257.5K | 0.39% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 11.0K | 0.44% |
| 7 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 3.6K | 0.33% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 39.7K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 17.6K | 0.48% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.96M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jin-Long Lin | GM, Senior Vice President & Director | 7M | male |
| Yi-Xun Li | Vice President & Director | 5M | male |
| Yi-Zhong Huang | Chief Financial Officer & Head of Accounting | 3M | male |
| Jia-Cheng Wu | Marketing and Product Manager | 2M | — |
| Yu-Zheng Wu | Head of the Production Department | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4107.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
